As editors at DengYue Med, we encounter countless stories of health and hope every day. These stories often remind me of patients suffering from cancer, who are not only fighting the disease but also striving to regain a normal life. Imagine a middle-aged patient whose life has been plunged into despair due to severe pain and mobility issues caused by a joint tumor. Perhaps you or your loved ones have experienced something similar.
Today, I want to share with you the breakthrough role of a drug called Pexidartinib in cancer treatment. It has not only brought medical innovation but also ignited a beacon of hope for many patients. At DengYue Med, we are committed to quality, compliance, and integrity, actively participating in the global market, not only helping domestically produced drugs reach overseas markets but also contributing to the health of people worldwide. This mission drives us to continuously introduce cutting-edge therapies like Pexidartinib, helping more people regain their vitality in life.
Pexidartinib is an oral targeted therapy, a CSF1R inhibitor, primarily targeting a rare joint tumor—tenosynovial giant cell tumor (TGCT). While usually benign, this tumor erodes joint tissue, causing severe pain, swelling, and functional impairment; many patients are even unable to perform daily activities. Traditional treatment mainly relies on surgery, but for cases with complex tumor locations or a high risk of recurrence, surgery is often ineffective and may even lead to more complications.
Clinical Validation:
Mr. Li, a TGCT patient who once faced the risk of amputation, can now write again. His joint tumor shrank by 68% on imaging, a change attributed to a small molecule drug targeting a specific signaling pathway.
A single oral capsule, taken twice daily, significantly relieved symptoms in 39% of 61 TGCT patients after 25 weeks, compared to zero in the placebo group. This drug, Pexidartinib, is the world's first approved CSF-1R inhibitor.
The advent of pexidartinib marks a shift in TGCT treatment from local intervention to systemic therapy, undoubtedly a major breakthrough in oncology. It reduces tumor volume by precisely inhibiting tumor cell growth signals, helping patients alleviate symptoms and improve their quality of life.
Long-term follow-up data show that the overall response rate in patients receiving pexidartinib treatment significantly improves over time. Based on tumor volume scoring, the response rate increased from an initial 56% to 68.1%, and the median reduction in target lesion diameter increased from 28% to 68%.
Even more encouragingly, the median duration of response has not yet been reached, with the longest follow-up time reaching 63.4 months. This means that many patients can maintain their remission for many years.
Evaluation Metric | Preliminary Results (Part 1) | Long-term Follow-up Results (Median 31.2 months) |
RECIST v1.1 ORR | 39% | 60.4% |
Tumor Volume Score (TVS) ORR | 56% | 68.1% |
Median Duration of Response (DOR) | – | Not reached (range: 0.03–63.4 months) |
Target Lesion Diameter – Median Reduction | 28% | 68% |
Regarding accessibility,
Pexidartinib, as the world's first CSF-1R inhibitor, validated the clinical feasibility of this target. It opened a new chapter in the treatment of tumor microenvironment, providing the first FDA-approved targeted therapy for patients with tenosynovial giant cell tumors.
Subsequent drug iterations, such as more selective CSF-1R inhibitors, have continued to drive this field forward. Innovative pharmaceutical companies in China have also actively participated in this global R&D wave.
These scientific breakthroughs, through bridges like DengYue Med in Hong Kong, can more efficiently benefit patients worldwide. Our professional drug quality inspection team and comprehensive import agency sales and operation system are becoming an important link in the global accessibility of innovative therapies.
From the laboratory to the pharmacy, from a groundbreaking scientific concept to a box of medicine in the hands of a patient, this journey requires the wisdom of scientists, the prudence of regulatory agencies, and the professionalism and reliability of pharmaceutical distribution companies.
DengYue Med will continue to uphold our corporate culture, safeguarding the health journey of every patient with quality and integrity, and contributing to the well-being of people worldwide. Let us together embrace a healthier tomorrow.
No comments:
Post a Comment